Targeting XPO1 for the treatment of MM: Real-world evidence

During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss exportin 1 (XPO1) as a target for the treatment of multiple myeloma (MM) with a focus on real-world evidence. The meeting opened with a presentation by Paul Richardson and featured a discussion including María-Victoria Mateos, Hang Quach, and Morie Gertz.

In the presentation, Dr Richardson discussed the role of XPO1 as a target for the treatment of relapsed/refractory MM. Richardson discussed the mechanism of action for XPO1 inhibitors, as well as the clinical trial data, and real-world experience associated with selinexor, a first-in-class selective inhibitor of nuclear export, in heavily pretreated patient populations. During the discussion, the steering committee members provided insight into combination regimens, strategies to manage toxicities, and the potential positioning of selinexor in current treatment algorithms for MM.

This educational resource is independently supported by Karyopharm. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.